

## REFERENCES

- Bao, T., Basal, C., Seluzicki, C., Li, S. Q., Seidman, A. D., & Mao, J. J. (2016). Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. *Breast Cancer Res Treat.* <https://pubmed.ncbi.nlm.nih.gov/27510185/>
- Basset, J., Inoue, S., Zimmet, P., Caterson, I., Chunming, C., Ikeda, Y., & Khalid, A. (2000). *The Asia Pacific Perspective: Redefining Obesity and Its Treatment.* Health Communication Australia Pty. [https://apps.who.int/iris/bitstream/handle/10665/206936/0957708211\\_eng.pdf?sequence=1&tnqh\\_x0026;isAllowed=y](https://apps.who.int/iris/bitstream/handle/10665/206936/0957708211_eng.pdf?sequence=1&tnqh_x0026;isAllowed=y)
- Blagosklonny, M. v., Schulte, T., Nguyen, P., Trepel, J., & Neckers, L. M. (1996). Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. *Cancer Research*, 56(8).
- Budiana, I. N. G., Angelina, M., & Pemayun, T. G. A. (2019). Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. *Journal of the Turkish-German Gynecological Association*, 20(1). <https://doi.org/10.4274/jtgga.galenos.2018.2018.0119>
- Clamp, A. R., James, E. C., McNeish, I. A., Dean, A., Kim, J. W., O'Donnell, D. M., Hook, J., Coyle, C., Blagden, S., Brenton, J. D., Naik, R., Perren, T., Sundar, S., Cook, A. D., Gopalakrishnan, G. S., Gabra, H., Lord, R., Dark, G., Earl, H. M., ... Ledermann, J. A. (2019). Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIg phase 3 randomised controlled trial. *The Lancet*, 394(10214). [https://doi.org/10.1016/S0140-6736\(19\)32259-7](https://doi.org/10.1016/S0140-6736(19)32259-7)
- Elattar, A., Bryant, A., Winter-Roach, B. A., Hatem, M., & Naik, R. (2011). Optimal primary surgical treatment for advanced epithelial ovarian cancer. In *Cochrane Database of Systematic Reviews* (Vol. 2011, Issue 8). <https://doi.org/10.1002/14651858.CD007565.pub2>
- Ezzi, M. S., Othieno-Abinya, N. A., Amayo, E., Oyiro, P., McLigeyo, A., Bett Yatich, R., & Shoba, B. (2019). Prevalence and predictors of cisplatin-induced peripheral neuropathy at the kenyatta national hospital. *Journal of Global Oncology*, 2019(5). <https://doi.org/10.1200/JGO.19.00097>
- Grogan, S., & Preuss, C. (2022). *Pharmacokinetics.* Stat Pearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK557744/#:~:text=Pharmacokin>

etics%20(PK)%20is%20the%20study, on%20the%20body%20more%20closely

- Kanat, O., Ertas, H., & Caner, B. (2017). Platinum-induced neurotoxicity: A review of possible mechanisms. In *World Journal of Clinical Oncology* (Vol. 8, Issue 4). <https://doi.org/10.5306/wjco.v8.i4.329>
- Marino, M., Jamal, Z., & Zito, P. (2022). *Pharmacodynamics*. Stat Pearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK507791/>
- Matz, M., Coleman, M. P., Sant, M., Chirlaque, M. D., Visser, O., Gore, M., Allemani, C., & Group, the W. C. (2016). The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). *Gynecol Oncol*. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195192/>
- Mikula-Pietrasik, J., Witucka, A., Pakula, M., Uruski, P., Begier-Krasińska, B., Niklas, A., Tykarski, A., & Książek, K. (2019). Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells. *Cellular and Molecular Life Science*, 681–697. <https://link.springer.com/article/10.1007/s00018-018-2954-1>
- Mikuła-Pietrasik, J., Witucka, A., Pakuła, M., Uruski, P., Begier-Krasińska, B., Niklas, A., Tykarski, A., & Książek, K. (2019). Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells. In *Cellular and Molecular Life Sciences* (Vol. 76, Issue 4). <https://doi.org/10.1007/s00018-018-2954-1>
- Mizrahi, D., Park, S. B., Li, T., Timmins, H. C., Trinh, T., Au, K., Battaglini, E., Wyld, D., Henderson, R. D., Grimison, P., Ke, H., Geelan-Small, P., Marker, J., Wall, B., & Goldstein, D. (2021). Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy. *JAMA Network Open*, 4(2). <https://doi.org/10.1001/jamanetworkopen.2020.36695>
- Molassiotis, A., Cheng, H. L., Leung, K. T., Li, Y. C., Wong, K. H., Au, J. S. K., Sundar, R., Chan, A., Ng, T. R. de, Suen, L. K. P., Chan, C. W., Yorke, J., & Lopez, V. (2019). Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. *Brain and Behavior*. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6576180/>
- Reeves, B. N., Dakhil, S. R., Sloan, J. A., Wolf, S. L., Burger, K. N., Kamal, A., Le-Lindqwister, N. A., Soori, G. S., Jaslowski, A. J., Kelaghan, J., Novotny, P. J., Lachance, D. H., & Loprinzi, C. L. (2012). Further data supporting that paclitaxel-associated acute pain syndrome is associated with

development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. *Cancer*, 118(20). <https://doi.org/10.1002/cncr.27489>

Siderov, J., & Kelly, A. (2018, September 17). *How is dosage of cancer therapy calculated for adults?* Clinical Oncology Society of Australia. [https://wiki.cancer.org.au/australia/Clinical\\_question:How\\_is\\_dosage\\_of\\_cancer\\_therapy\\_calculated\\_for\\_adults%3F](https://wiki.cancer.org.au/australia/Clinical_question:How_is_dosage_of_cancer_therapy_calculated_for_adults%3F)

Suzuki, M. (2013). Peripheral neuropathy in the elderly. *Handbook of Clinical Neurology*. <https://pubmed.ncbi.nlm.nih.gov/23931816/>

Telessy, I. G., & Buttar, H. S. (2018). Obesity related alterations in pharmacokinetics and pharmacodynamics of drugs: emerging clinical implications in obese patients - part II. *Adipobiology*, 9(0). <https://doi.org/10.14748/adipo.v9.4990>

Wong, M. L., Cooper, B. A., Paul, S. M., Abrams, G., Topp, K., Kober, K. M., Chesney, M. A., Mazor, M., Schumacher, M. A., Conley, Y. P., Levine, J. D., & Miaskowski, C. (2019). Age-related differences in patient-reported and objective measures of chemotherapy-induced peripheral neuropathy among cancer survivors. *Support Care Cancer*. <https://pubmed.ncbi.nlm.nih.gov/30770977/>

Zajaczkowska, R., Kocot-Kępska, M., Leppert, W., Wrzosek, A., Mika, J., & Wordliczek, J. (2019). Mechanisms of chemotherapy-induced peripheral neuropathy. In *International Journal of Molecular Sciences* (Vol. 20, Issue 6). <https://doi.org/10.3390/ijms20061451>